AVENTURA, Fla. and NATICK, Mass., Dec. 9, 2022 /PRNewswire/ -- Cytovia Inc.(DBA Cytovia Therapeutics, Inc.), a biopharmaceutical company focused on unlocking the power of natural killer (NK) cell therapeutics through bispecific antibodies and TALEN® gene-edited, iPSC-derived NK (iNK) cells, today announced new preclinical data for its CD38-targeted Flex-NK™ bispecific antibody at the American Society of Hematology's 64th Annual Meeting (ASH 2022) taking place in New Orleans, LA, and virtually December 10-13th, 2022.
Cytovia Therapeutics Presents New Data on CD38-Targeted Flex-NK™ Bispecific Antibody at 2022 American Society of Hematology Annual Meeting
AVENTURA, Fla. and NATICK, Mass., Nov. 7, 2022 /PRNewswire/ -- Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and bispecific antibodies, today announced new preclinical data for its TALEN® gene-edited, iPSC-derived NK (iNK) cells and GPC3-targeted Flex-NK™ bispecific antibodies. The data will be presented at the Society for Immunotherapy of Cancer's 37th Annual Meeting (SITC 2022) taking place in Boston, MA, and virtually November 8-12th, 2022.
AVENTURA, Fla. and NATICK, Mass., Oct. 27, 2022 /PRNewswire/ -- Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, announced today that it will be presenting new preclinical data for its CD38-targeted Flex-NK™ cell engager antibodies at the American Society of Hematology's 64th Annual Meeting (ASH 2022) taking place in New Orleans, LA, and virtually December 10-13th, 2022.
AVENTURA, Fla. and NATICK, Mass., Sept. 12, 2022 /PRNewswire/ -- Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, announced today that it is presenting new preclinical data for its GPC3 Flex-NK™ cell engager antibody in combination with natural killer cells at the European Society of Medical Oncology's annual congress in Paris, France on September 12th, 2022.
Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and...
AVENTURA, Fla. and NATICK, Mass., April 8, 2022 /PRNewswire/ -- Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, announced today that the novel data it is presenting at the American Association of Cancer Research's annual meeting in New Orleans on April 12th, 2022 is now available on both the AACR and Cytovia websites.
AVENTURA, Fla. and NATICK, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell...
AVENTURA, Fla. and NATICK, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell...